RxDoctor Payments Data

Narinder Batra, MD

Cardiovascular Disease · Los Angeles, CANPI 1750307658

Payments from drug & device makers

$3,892in general payments, 2019–2025

Across 130 payments — averaging $29.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$812
  • Boston Scientific$808
  • Novartis$637
  • Pfizer$372
  • Shockwave Medical, Inc$317
  • Abbott$225
  • plus $720 from 12 others

What the payments were for

  • Grants$1003%
  • Food & beverage$3,78097%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,892 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$218,557
Medicare patients
339
Services billed
1,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan317$374,228
EliquisApixaban309$318,416
JardianceEmpagliflozin237$277,261
XareltoRivaroxaban82$91,227
Repatha SureclickEvolocumab31$23,162
Repatha PushtronexEvolocumab26$20,100
FarxigaDapagliflozin Propanediol16$13,476
BrilintaTicagrelor15$11,437
Metoprolol Succinate632$9,211
InpefaSotagliflozin11$7,339
Praluent PenAlirocumab13$6,637
Amiodarone Hcl150$5,066
Clonidine35$4,729
Losartan Potassium312$3,433
Atorvastatin Calcium390$2,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$637$374,228317 claims
PfizerEliquis$372$318,416309 claims
Boehringer IngelheimJardiance$812$277,261237 claims
Johnson & JohnsonXarelto$168$91,22782 claims
Lexicon Pharmaceuticals, Inc.Inpefa$149$7,33911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →